Mobec (Meloxicam)

Meloxicam, the active ingredient in Mobec, is a nonsteroidal anti-inflammatory drug presented as an oral dosage form for oral use. It is used to relieve pain and inflammation associated with osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute musculoskeletal pain in adult patients. GNH USA supplies Mobec as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meloxicam is an NSAID that targets inflammatory joint and musculoskeletal conditions. - Osteoarthritis: reduces joint pain and swelling, helping improve function. - Rheumatoid arthritis: diminishes systemic inflammation and joint damage progression. - Ankylosing spondylitis: alleviates spinal stiffness and pain. - Acute pain: provides rapid relief of moderate to severe pain from injuries or postoperative settings.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Gastrointestinal discomfort such as dyspepsia or nausea. - Headache or dizziness. - Mild skin rash or pruritus. - Peripheral edema. - Elevated liver enzymes.

Serious or Rare Side Effects: - Gastrointestinal ulceration or bleeding. - Severe hypersensitivity reactions including Stevens‑Johnson syndrome. - Cardiovascular events such as myocardial infarction or stroke. - Renal impairment or failure. - Hepatotoxicity with jaundice.

Before prescribing Meloxicam, consider patient‑specific risk factors and monitor appropriately. - Cardiovascular risk: avoid in patients with recent myocardial infarction or uncontrolled hypertension. - Gastrointestinal risk: use caution in those with a history of ulcers or bleeding. - Renal function: monitor serum creatinine in patients with renal impairment. - Hepatic disease: assess liver enzymes periodically. - Pregnancy and lactation: avoid unless clearly needed and benefits outweigh risks. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Meloxicam can affect the safety or efficacy of several co‑administered medicines.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Other NSAIDs or COX‑2 inhibitors: heightened gastrointestinal toxicity. - Selective serotonin reuptake inhibitors (SSRIs): additive bleeding potential.

Moderate Interactions (Monitor Closely):\n- ACE inhibitors or ARBs: possible reduction in renal function. - Diuretics: may enhance nephrotoxic effects. - Lithium: increased serum lithium levels. - Methotrexate: reduced clearance leading to toxicity.